The Cancer Center Administration team provides centralized infrastructure and support that enables the City of Hope Comprehensive Cancer Center to function effectively, efficiently, and cohesively. Administration works with other Center leadership to foster collaborations, and support cancer focused research through infrastructure, pilot projects, and faculty recruitment. Administration's specific duties include: * Administrative planning to promote and facilitate scientific collaborations and interactions * Strategic planning leadership and implementation of initiatives * Management and evaluation of Cancer Center Membership * Fiscal control and management of Cancer Center accounts ensuring compliance with all COH institutional policies and federal requirements * Management, logistics support and documentation of senior leadership committees, retreats and programmatic meetings * Coordination of information technology required for internal and external data reporting *Coordination of planning and evaluation of Shared Resources * Management, processing and monitoring of CC pilot project competitions *Cataloguing of all CC programmatic meetings and retreats Recent accomplishments of the Administration Team include successful development of new Shared Resources and establishment of a new Shared Resources reporting system, review/restructure of membership, and completion of a new strategic plan. Funding is requested to cover a portion of the salary for these efforts and to cover a portion of the costs for the Cancer Center seminar series. The majority of the costs for Administration are covered by institutional funds. The Administration budget request represents 4.1% of the overall CCSG budget requested in this application.
Cancer Center Administration provides centralized leadership and support for multiple functions including strategic planning, membership, pilot project competitions, educational seminars, senior leadership meetings and Shared Resources. This responsibility enhances the Cancer Center's dedication to providing a leadership structure which contributes to the coordination and collaboration of research efforts.
|Aslamy, Arianne; Oh, Eunjin; Ahn, Miwon et al. (2018) Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. J Clin Endocrinol Metab 103:1966-1976|
|Abeywardana, Tharindumala; Oh, Myungeun; Jiang, Lei et al. (2018) CARM1 suppresses de novo serine synthesis by promoting PKM2 activity. J Biol Chem 293:15290-15303|
|Sun, Virginia; Crane, Tracy E; Slack, Samantha D et al. (2018) Rationale, development, and design of the Altering Intake, Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors. Contemp Clin Trials 68:61-66|
|Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334|
|Caserta, Enrico; Chea, Junie; Minnix, Megan et al. (2018) Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood 131:741-745|
|Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96|
|Jandial, Rahul; Neman, Josh; Lim, Punnajit P et al. (2018) Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. Int J Mol Sci 19:|
|Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730|
|Salgia, Ravi; Kulkarni, Prakash; Gill, Prakash S (2018) EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 1869:128-137|
|Choi, Audrey H; O'Leary, Michael P; Lu, Jianming et al. (2018) Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics 9:22-29|
Showing the most recent 10 out of 1396 publications